Breaking AI & Tech News Analyzed

Legal Threats Emerge Over UK‑US Drug Pricing AgreementCampaigners Global Justice Now and Just Treatment have issued a nine‑page “letter before claim” stating they will pursue a judicial review if the Department of Health and Social Care (DHSC) does not repeal a statutory instrument that lets the health secretary overrule the independent judgment of NICE on NHS drug prices.Statutory Instrument Gives Ministers Power to Override NICEThe secondary legislation came into force last month, granting ministers authority to direct how much the NHS should pay for certain medicines.Both groups argue this constitutes an “unlawful power grab” that breaches the Health and Social Care Act 2012.Former health secretary Andrew Lansley has also labelled the instrument unlawful.Opaque Cost Data Undermines Parliamentary ScrutinyMPs from multiple parties have criticised the government’s refusal to publish an impact assessment of the decade‑long UK‑US deal.No concrete figures on the long‑term cost to the NHS have been released, limiting debate in the Commons.Potential Erosion of NICE Independence Risks NHS Price ControlsNICE is globally respected for its independent cost‑effectiveness assessments.Overriding its recommendations could lead to higher drug prices for the NHS, undermining the mechanism that keeps “big pharma’s overinflated prices” in check.Campaigners warn the move jeopardises patient safety and democratic oversight.Future Legal Battles May Shape UK Drug Policy LandscapeIf the judicial review proceeds, courts will examine whether the statutory instrument conflicts with existing health legislation.Continued parliamentary pressure may force the government to renegotiate aspects of the UK‑US tariff‑free drug export agreement.The outcome could set a precedent for how future health‑related secondary legislation is crafted and scrutinised.

MPs Challenge New Ministerial Power Over NHS Drug PricingThirty‑one MPs from Labour, the Greens, the Liberal Democrats, the SNP, Plaid Cymru and independents have signed a House of Commons motion opposing a statutory instrument that gives Wes Streeting the authority to tell the National Institute for Health and Care Excellence (NICE) which cost‑effectiveness threshold to apply when appraising new medicines.The opposition frames the change as a “power grab” that could erode the agency’s role as an international benchmark for value‑for‑money drug decisions.Numbers Behind the Opposition31 MPs have signed the motion.The statutory instrument was issued in 2026 as part of a broader UK‑US drug‑pricing deal.Health experts warn the deal could add billions of pounds to the NHS drug bill.Potential Consequences for NHS Funding and Drug RegulationCritics, including former health secretary Andrew Lansley, argue the new power may conflict with the Health and Social Care Act 2012, which protects NICE’s independence. If the threshold is lowered, pharmaceutical companies could secure higher prices, forcing the NHS to divert funds from other services such as surgeries or nursing staff.Think‑tanks like the Health Foundation warn that a larger drug spend will trigger “difficult cuts” to preventative and primary‑care programmes.What the Next Parliamentary Battles May HoldWith the motion tabled as a “prayer”—a formal way for MPs to register dissent on secondary legislation—the opposition could pressure the government to amend or repeal the instrument. John McDonnell and other senior Labour figures have signalled readiness to push for a full debate in the Commons, while the House of Lords may see a “motion of regret” from Lord Lansley.If the government persists, legal challenges could arise over the compatibility of the statutory instrument with existing health law, potentially leading to judicial review.